ImmunoGen, Inc.
(NASDAQ : IMGN)

( )
IMGN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.61%93.101.3%$988.29m
BIIBBiogen Inc.
-2.52%224.401.3%$650.41m
AMGNAmgen Inc.
-0.81%178.301.3%$468.17m
GILDGilead Sciences, Inc.
-0.38%62.800.9%$434.85m
ILMNIllumina, Inc.
-2.34%314.523.5%$280.91m
REGNRegeneron Pharmaceuticals, Inc.
-1.07%340.462.6%$279.54m
VRTXVertex Pharmaceuticals Incorporated
-1.59%172.581.9%$238.29m
ALXNAlexion Pharmaceuticals, Inc.
-1.72%130.092.0%$169.34m
EXASExact Sciences Corporation
1.27%95.1325.3%$167.52m
AAgilent Technologies, Inc.
0.30%75.791.6%$145.62m
SRPTSarepta Therapeutics, Inc.
0.06%118.1614.7%$133.09m
ONCESpark Therapeutics, Inc.
0.06%110.6711.2%$117.72m
INCYIncyte Corporation
-2.51%73.522.5%$96.42m
IONSIonis Pharmaceuticals, Inc.
-2.23%73.338.3%$95.85m
BMRNBioMarin Pharmaceutical Inc.
-0.59%85.494.3%$92.14m

Company Profile

ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.